Amylyx ALS drug draws criticism over $158,000 price tag
pharmaphorum
OCTOBER 3, 2022
The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day prescription. Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost.
52 
Let's personalize your content